Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR trials, which is the importance of early triplet therapy for relapsed patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Advertisement